Strontium ranelate

STEROID REPLACEMENT THERAPY Anticancer and Immunomodulating Drugs, Other immunomodulating drugs STRONTIUM RANELATE  

STRONTIUM RANELATE ANTIBIOTICS -QUINOLONES, TETRACYCUNES i levels of these antibiotics 1 absorption Avoid co-administration 

---

Strontium ranelate is an oral agent possessing bone-forming and antiresorptive properties. Some data suggest significant reductions in vertebral fractures.46 However, the benefit in nonvertebral fractures is unclear. This agent has not yet been approved for use by the FDA. 

Finally, in very severe cases, the alternative to a bone remodeling agent such as teriparatide should be taken into consideration. The place for strontium ranelate, a substance without age-related contraindications, remains to be established as clinical experience in its use grows. 

Strontium ranelate is administered as 2 g once daily. In 24 weeks, the patient would require 6 packs of 28 sachets. If one pack of 28 sachets costs 47.12, 6 packs cost 282.72 (47.12 x 6). 

Strontium Ranelate Granules For post-menopausal women with osteoporosis... 

Thus, we now have several well-validated, efficacious forms of treatment for this common debilitating disease. In Europe, strontium ranelate has been used for several years with favorable results in large clinical trials approval for use in the USA is expected. 

Strontium ranelate has not been approved in the United States for the treatment of osteoporosis but is being used in Europe, generally at a dose of 2 g/d. Denosumab, an antibody to RANKL that suppresses bone resorption by interfering with RANKL/RANK induction of osteoclast differentiation and function, has shown good efficacy in phase 3 trials and may be approved for clinical use in the near future. 

Meunier PJ et al The effects of strontium ranelate on the risk of vertebral fractures in women with postmenopausal osteoporosis. N Engl J Med 2004 350 459. [PMID 14749454]... 

Strontium ranelate - must be taken on an empty stomach as it chelates with metal ions in food. 

NICE (National Institute for Health and Clinical Excellence) (2008). Osteoporosis -Secondary prevention including strontium ranelate. Available at http //www.nice. org.uk/guidance/TA161/guidance/pdf/English/ [Accessed 4 July 2008],... 

Options for treatment include hormone replacement therapy (HRT), bisphosphonates, calcitriol, calcitonin, raloxifene, strontium ranelate, and teriparatide. Hormone replacement therapy is generally indicated for women who are under 50 years and are experiencing a premature menopause. Symptomatic menopausal women may opt to use HRT also, as the benefits outweigh the risks for up to 5 years treatment. They may choose an alternative treatment for osteoporosis if preferred. Hormone replacement therapy is not recommended for first line treatment for long-term prevention of osteoporosis in women over 50 years of age. 

Strontium ranelate is a relatively new product which has a dual action. It works by reducing bone resorption and by increasing bone formation. It is available in a sachet and is mixed in water. 

In patients who cannot tolerate bisphosphonates and who have a combination of other risk factors, raloxifene or strontium ranelate may be an alternative. See NICE guidance for further information. 

In women aged 75 years and older, treatment is recommended without the need for prior dual energy X-ray absorptiometry (DXA) scanning. Bisphosphonates, strontium ranelate, and raloxifene are all suitable for initiation in primary care. However both SIGN (2003) and NICE (2008) recommend that a bisphosphonate (alendronate, etidronate, risedronate, ibandronate) should be used first-line. 

Raloxifene is recommended in patients (NICE, 2008) in whom bisphosphonates are contraindicated, those who cannot comply with the requirements needed to take bisphosphonates, or who have had an unsatisfactory response or are intolerant of bisphosphonates. Strontium ranelate is a suitable alternative if a bisphosphonate cannot be taken. However, NICE guidelines on secondary prevention of osteoporosis does not currently recommend the use of strontium ranelate. 

Strontium ranelate is a suitable alternative if a bisphosphonate cannot be taken. 

Raloxifene can be considered if both a bisphosphonate and strontium ranelate cannot be given. 

Although Mrs GG may not wish to take a bisphosphonate she may be persuaded to take calcium with or without vitamin D which is effective although less effective than a bisphosphonate. It is a cheaper and less toxic option. Other options such as teriparatide and strontium ranelate are more expensive and there is less experience in their use but they should be discussed with Mrs GG. 

Strontium citrate, an alternative oral treatment with proven efficacy. In laboratory experiments, strontium ranelate was shown to stimulate the proliferation of osteoblasts, as well as inhibit the proliferation of osteoclasts. 

Olanzapine, already mentioned in CHEC-II(1996), has become one of the most commonly used atypical anti-psychotics. Strontium ranelate <2005MI728> has emerged as a novel medication in the treatment of osteoporosis. It increases the synthesis of collagen and noncollagenic proteins in vivo. 

TETRACYCLINES STRONTIUM RANELATE 1 levels of these antibiotics i absorption Avoid co-administration... 

In addition may medication related to the uremic state lead to important trace element accumulation. In the past this has clearly been established for aluminum resulting from the use of aluminum hydroxide as a phosphate binding agent. As aluminum-based phosphate binders may be contaminated with other elements, e.g. strontium the possibility for a simultaneous accumulation of different elements has been suggested [7]. Strontium is mainly eliminated by the kidney and has been associated with bone mineralization defects when present at high concentrations. In view of this the use of strontium ranelate for the treatment and preven-... 

Clinically important, potentially hazardous interactions with acitretin, aluminum hydroxide, amoxicillin, ampicillin, antacids, bacampicillin, betamethasone, bismuth, bromelain, calcium, carbenicillin, cholestyramine, doxacillin, corticosteroids, dairy products, dicloxacillin, didanosine, digoxin, food, glidazide, iron, isotretinoin, methicillin, methotrexate, methoxyflurane, mezlocillin, nafcillin, oxacillin, penicillins, piperacillin, retinoids, rocuronium, strontium ranelate, sucralfate, ticarcillin, vitamin A, zinc... 

Strodin Stromba Stromectol strontium ranelate Strumazol Stubit Stugeron Sublimaze Suboxone Subutex Sucaryl succimer succinylcholine Sucrabest sucralfate... 

Drugs currently used to treat osteoporosis are classified into those that inhibit osteoclastic bone resorption (including bisphos-phonates, denosumab, and selective estrogen receptor modulators) and those that stimulate bone formation by osteoblasts (parathyroid hormone and derivatives, such as teriparatide). Strontium ranelate may have a dual effect. Other drugs being tested in clinical trials include inhibitors of cathepsin K (an osteoclastic enzyme critical for bone resorption) and of sclerostin (a negative modulator of the Wnt pathway) [21],... 

Strontium stimulates bone formation and decreases bone resorption. In a preliminary study of postmenopausal women with severe osteoporosis, strontium ranelate 1 g twice daily or 2 g once daily reduced new vertebral fractures by 41%, and increased lumbar spine BMD by 14% and femoral neck BMD by 8% compared with placebo. Nonvertebral fracture rates were similar. Diarrhea was more common in the strontium group. Small decreases in serum calcium and PTH, small increases in serum phosphate, and transient increases in creatine kinase were measured. 

---